Novel GLP-1 receptor agonists for diabetes

Bibliography

• World Health Organization. Obesity and overweight. Available from: http://www who int/mediacentre/factsheets/fs311/en/index html,2010 [Last accessed 21 December 2010]
   Google Scholar
• Department of health and Human Services. Centers for Disease Control and Prevention. National Diabetes Fact Sheet. Available from: http://www cdc gov/diabetes/pubs/pdf/ndfs_2007 pdf,2007 [Last accessed 12 January 2011]
   Google Scholar
• Fox CS, Pencina MJ, Meigs JB, Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham Heart Study. Circulation 2006;113:2914-18
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. National Diabetes Statistics, 2007. Available from: http://www diabetes niddk nih gov/dm/pubs/statistics/index htm,2010 [Last accessed 21 December 2010]
   Google Scholar
• Girard J. The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions. Diabetes Metab 2008;34:550-9
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of Medical Care in Diabetes - 2008. Diabetes Care 2008;31:S12-54
   PubMed Web of Science ®Google Scholar
• Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest 2007;117:24-32
   PubMed Web of Science ®Google Scholar
• Brubaker PL, Anini Y. Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. Can J Physiol Pharmacol 2003;81:1005-12
   PubMed Web of Science ®Google Scholar
• Hansen L, Lampert S, Mineo H, Holst JJ. Neural regulation of glucagon-like peptide-1 secretion in pigs. Am J Physiol Endocrinol Metab 2004;287:E939-47
   PubMed Web of Science ®Google Scholar
• Vahl TP, Drazen DL, Seeley RJ, Meal-anticipatory glucagon-like peptide-1 secretion in rats. Endocrinology 2010;151:569-75
   PubMed Web of Science ®Google Scholar
• Tolhurst G, Reimann F, Gribble FM. Nutritional regulation of glucagon-like peptide-1 secretion. J Physiol 2009;587:27-32
   PubMed Web of Science ®Google Scholar
• Buteau J. GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival. Diabetes Metab 2008;34(Suppl 2):S73-7
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 2003;17:161-71
   PubMed Web of Science ®Google Scholar
• Aaboe K, Krarup T, Madsbad S, Holst JJ. GLP-1: physiological effects and potential therapeutic applications. Diabetes Obes Metab 2008;10:994-1003
   PubMed Web of Science ®Google Scholar
• Holst JJ, Deacon CF, Vilsboll T, Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol Med 2008;14:161-8
   PubMed Web of Science ®Google Scholar
• Pannacciulli N, Bunt JC, Koska J, Higher fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans. Am J Clin Nutr 2006;84:556-60
   PubMed Web of Science ®Google Scholar
• Grieve DJ, Cassidy RS, Green BD. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol 2009;157:1340-51
   PubMed Web of Science ®Google Scholar
• Nikolaidis LA, Mankad S, Sokos GG, Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109:962-5
   PubMed Web of Science ®Google Scholar
• Sokos GG, Nikolaidis LA, Mankad S, Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006;12:694-9
   PubMed Web of Science ®Google Scholar
• Madsbad S. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)–preclinical and clinical results. Best Pract Res Clin Endocrinol Metab 2009;23:463-77
   PubMed Web of Science ®Google Scholar
• Holst JJ, Burcelin R, Nathanson E. Neuroprotective properties of GLP-1: theoretical and practical applications. Curr Med Res Opin 2011;27:547-58
   PubMed Web of Science ®Google Scholar
• Vaag A. On the pathophysiology of late onset non-insulin dependent diabetes mellitus. Current controversies and new insights. Dan Med Bull 1999;46:197-234
   PubMed Web of Science ®Google Scholar
• Vilsboll T, Holst JJ, Knop FK. The spectrum of antidiabetic actions of GLP-1 in patients with diabetes. Best Pract Res Clin Endocrinol Metab 2009;23:453-62
   PubMed Web of Science ®Google Scholar
• Christensen M, Knop FK. Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide? Curr Diab Rep 2010;10:124-32
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Buse JB, Taylor K, Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372:1240-50
   PubMed Web of Science ®Google Scholar
• Garg SK. The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes–a comprehensive review. Diabetes Technol Ther 2010;12:11-24
   PubMed Web of Science ®Google Scholar
• Penfornis A, Borot S, Raccah D. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies. Diabetes Metab 2008;34(Suppl 2):S78-90
   PubMedGoogle Scholar
• Davidson JA. Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. Cleve Clin J Med 2009;76(Suppl 5):S28-38
   PubMedGoogle Scholar
• Behme MT, Dupre J, McDonald TJ. Glucagon-like peptide 1 improved glycemic control in type 1 diabetes. BMC Endocr Disord 2003;3:3
   PubMedGoogle Scholar
• Dupre J, Behme MT, McDonald TJ. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. J Clin Endocrinol Metab 2004;89:3469-73
   PubMed Web of Science ®Google Scholar
• Rother KI, Spain LM, Wesley RA, Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabetes Care 2009;32:2251-7
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Sherman SI, Bergenstal RM, Buse JB. The safety of incretin-based therapies–review of the scientific evidence. J Clin Endocrinol Metab 2011;96:2027-31
   PubMed Web of Science ®Google Scholar
• Chen YE, Drucker DJ. Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. J Biol Chem 1997;272:4108-15
   PubMed Web of Science ®Google Scholar
• Byetta Summary of Product Characteristics. Available from: http://www ema europa eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000698/WC500051845 pdf,2010 [Last accessed 16 December 10 A.D]
   Google Scholar
• DeFronzo RA, Ratner RE, Han J, Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100
   PubMed Web of Science ®Google Scholar
• Buse JB, Henry RR, Han J, Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35
   PubMed Web of Science ®Google Scholar
• Kendall DM, Riddle MC, Rosenstock J, Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91
   PubMed Web of Science ®Google Scholar
• Barnett AH, Burger J, Johns D, Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007;29:2333-48
   PubMed Web of Science ®Google Scholar
• Heine RJ, Van Gaal LF, Johns D, Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-69
   PubMed Web of Science ®Google Scholar
• Nauck MA, Duran S, Kim D, A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007;50:259-67
   PubMed Web of Science ®Google Scholar
• Klonoff DC, Buse JB, Nielsen LL, Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275-86
   PubMed Web of Science ®Google Scholar
• Buse JB, Bergenstal RM, Glass LC, Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011;154:103-12
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Okerson T, Viswanathan P, Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008;24:2943-52
   PubMed Web of Science ®Google Scholar
• Mikhail N. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2008;17:845-53
   PubMed Web of Science ®Google Scholar
• Bradley DP, Kulstad R, Schoeller DA. Exenatide and weight loss. Nutrition 2010;26:243-9
   PubMed Web of Science ®Google Scholar
• Malone J, Trautmann M, Wilhelm K, Exenatide once weekly for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2009;18:359-67
   PubMed Web of Science ®Google Scholar
• Kim D, MacConell L, Zhuang D, Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007;30:1487-93
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. EMA Assessment Report for Bydureon; 2011
   Google Scholar
• Buse JB, Drucker DJ, Taylor KL, DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010;33:1255-61
   PubMed Web of Science ®Google Scholar
• Blevins T, Pullman J, Malloy J, DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011;96:1301-10
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Wysham C, MacConell L, Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376:431-9
   PubMed Web of Science ®Google Scholar
• Wysham C, Bergenstal R, Malloy J, DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med 2011;28:705-14
   PubMed Web of Science ®Google Scholar
• Diamant M, Van GL, Stranks S, Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010;375:2234-43
   PubMed Web of Science ®Google Scholar
• Buse JB, Nauck M, Forst T, Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomised, open-label study. Presented at the European Association for the Study of Diabetes (EASD), 12-16 September 2011 Abstract No. 75
   Google Scholar
• Eli Lilly. DURATION-6 Top-Line Study Results Announced. 2011
   Google Scholar
• Deyoung MB, MacConell L, Sarin V, Encapsulation of Exenatide in Poly-(d,l-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes. Diabetes Technol Ther 2011; published online; doi:10.1089/dia.2011.0050 [doi]
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Guidance for Industry. E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Available from: http://www fda gov/downloads/RegulatoryInformation/Guidances/ucm129357 pdf,2005 [Last accessed 6 January 11 A.D]
   Google Scholar
• Knudsen LB, Nielsen PF, Huusfeldt PO, Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000;43:1664-9
   PubMed Web of Science ®Google Scholar
• Knudsen LB. Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes. J Med Chem 2004;47:4128-34
   PubMed Web of Science ®Google Scholar
• Madsen K, Knudsen LB, Agersoe H, Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. J Med Chem 2007;50:6126-32
   PubMed Web of Science ®Google Scholar
• Victoza Summary of product characteristics. Available from: http://www ema europa eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001026/WC500050017 pdf,2010 [Last accessed 15 December 2010]
   Google Scholar
• Drab SR. Clinical studies of liraglutide, a novel, once-daily human glucagon-like peptide-1 analog for improved management of type 2 diabetes mellitus. Pharmacotherapy 2009;29:43S-54S
   PubMed Web of Science ®Google Scholar
• Garber A, Henry R, Ratner R, Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-81
   PubMed Web of Science ®Google Scholar
• Marre M, Shaw J, Brandle M, Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-78
   PubMed Web of Science ®Google Scholar
• Nauck M, Frid A, Hermansen K, Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84-90
   PubMed Web of Science ®Google Scholar
• Zinman B, Gerich J, Buse JB, Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224-30
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Vaag A, Schmitz O, Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009;52:2046-55
   PubMed Web of Science ®Google Scholar
• Buse JB, Rosenstock J, Sesti G, Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47
   PubMed Web of Science ®Google Scholar
• Montanya E, Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin Ther 2009;31:2472-88
   PubMed Web of Science ®Google Scholar
• Neumiller JJ, Campbell RK. Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. Ann Pharmacother 2009;43:1433-44
   PubMed Web of Science ®Google Scholar
• Christensen M, Knop FK, Holst JJ, Vilsboll T. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs 2009;12:503-13
   PubMed Web of Science ®Google Scholar
• Ratner RE, Rosenstock J, Boka G. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med 2010;27:1024-32
   PubMed Web of Science ®Google Scholar
• Christensen M, Knop FK, Vilsboll T. The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist. Expert Rev Endocrinol Metab 2011;6:513-25
   Google Scholar
• Sanofi-aventis. Once-Daily Lixisenatide in Combination with Basal Insulin Demonstrates Significant Improvement in Glucose Control. Available from: http://en sanofi-aventis com/binaries/20100930_GETGOAL_en_tcm28-29296 pdf,2010 [Last accessed 7 January 2011]
   Google Scholar
• ClinicalTrials.gov. www clinicaltrials gov, 2010. Available from: www.clinicaltrials.gov [Last accessed 29 November 2010]
   Google Scholar
• Zealand Pharma A/S. Zealand Pharma Announces An Extension of The Lixisenatide Global Licensing Agreement with sanofi-aventis for Type-2 Diabetes. Available from: http://www marketwire com/press-release/Zealand-Pharma-Announces-An-Extension-The-Lixisenatide-Global-Licensing-Agreement-with-1272421 htm,2010 [Last accessed 7 January 2011]
   Google Scholar
• Matthews JE, Stewart MW, De Boever EH, Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab 2008;93:4810-17
   PubMed Web of Science ®Google Scholar
• Seino Y, Nakajima H, Miyahara H, Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus. Curr Med Res Opin 2009;25:3049-57
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Reusch J, Bush M, Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 2009;32:1880-6
   PubMed Web of Science ®Google Scholar
• St Onge EL, Miller SA. Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes. Expert Opin Biol Ther 2010;10:801-6
   PubMed Web of Science ®Google Scholar
• Tomkin GH. Albiglutide, an albumin-based fusion of glucagon-like peptide 1 for the potential treatment of type 2 diabetes. Curr Opin Mol Ther 2009;11:579-88
   PubMed Web of Science ®Google Scholar
• Retterstol K. Taspoglutide: a long acting human glucagon-like polypeptide-1 analogue. Expert Opin Investig Drugs 2009;18:1405-11
   PubMed Web of Science ®Google Scholar
• Kapitza C, Heise T, Birman P, Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes. Diabet Med 2009;26:1156-64
   PubMed Web of Science ®Google Scholar
• Nauck MA, Ratner RE, Kapitza C, Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. Diabetes Care 2009;32:1237-43
   PubMed Web of Science ®Google Scholar
• Ratner R, Nauck M, Kapitza C, Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study. Diabet Med 2010;27:556-62
   PubMed Web of Science ®Google Scholar
• Dennis M. Roche stops dosing patients in late-stage taspoglutide studies. Available from: http://www firstwordplus com/Fws do?articleid=1BE3E9330CB840FEBFFED2DFB527ED71,2010 Available from: http://www.firstwordplus.com/Fws.do?articleid=1BE3E9330CB840FEBFFED2DFB527ED71 [Last accessed 22 August 2011]
   Google Scholar
• Torsoli A. Roche said to return diabetes drug rights to Ipsen. Bloomberg. Available from: http://www businessweek com/news/2011-02-01/roche-said-to-return-diabetes-drug-rights-to-ipsen html,2011
   Google Scholar
• Bell DS. A comparison of agents used to manage type 2 diabetes mellitus: need for reappraisal of traditional approaches. Treat Endocrinol 2004;3:67-76
   PubMedGoogle Scholar
• Maedler K, Carr RD, Bosco D, Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005;90:501-6
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Jellinger PS, Davidson JA, Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59
   PubMed Web of Science ®Google Scholar
• Knowler WC, Fowler SE, Hamman RF, 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374:1677-86
   PubMed Web of Science ®Google Scholar
• Bode BW, Testa MA, Magwire M, Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:604-12
   PubMed Web of Science ®Google Scholar
• Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007;28:187-218
   PubMed Web of Science ®Google Scholar